<DOC>
	<DOCNO>NCT02639091</DOCNO>
	<brief_summary>Determine safety , tolerability maximum tolerate dose anetumab ravtansine ( BAY 94-9343 ) combination pemetrexed 500 mg/m2 cisplatin 75 mg/m2 subject mesothelin-expressing predominantly epithelial mesothelioma nonsquamous non-small-cell lung cancer .</brief_summary>
	<brief_title>Phase Ib Study Anetumab Ravtansine Combination With Pemetrexed Cisplatin Mesothelin-expressing Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Maytansine</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<mesh_term>Immunoconjugates</mesh_term>
	<criteria>Subjects may male female , must age =/ &gt; 18 year date signing informed consent form . Subjects must histologically confirm , unresectable , locally advanced metastatic pleural peritoneal predominantly ( &gt; 50 % tumor component ) epithelial mesothelioma nonsquamous nonsmallcell lung cancer ( NSCLC ) . Both chemotherapynaive previously treat subject eligible ; however , newly diagnose NSCLC subject eligible FDAapproved therapy receive enrollment ( e.g . subject epidermal growth factor receptor [ EGFR ] mutate anaplastic lymphoma kinase [ ALK ] translocate NSCLC receive FDAapproved targeted therapy ) . Subjects must least 1 measurable evaluable tumor lesion accord RECIST 1.1 ( nonsquamous NSCLC ) mRECIST ( epithelial pleural mesothelioma ) . Subjects resect primary tumor document metastasis eligible . Subjects must life expectancy least 12 week . Subjects must ECOG ( Eastern Cooperative Oncology Group performance Status 0 1 Subjects must adequate bone marrow , liver , kidney , coagulation function . Subjects previous concurrent cancer distinct primary site histology cancer evaluate study , previous cancer curatively treat &lt; 3 year start study Treatment . Subjects history current evidence bleeding disorder , i.e . hemorrhage / bleed event CTCAE ( Common Terminology Criteria Adverse Events ) Grade ≥2 within 4 week start study Treatment . Subjects new progressive brain meningeal spinal metastasis . Subjects history current evidence uncontrolled cardiovascular disease i.e . NYHA ( New York Heart Association ) Class III IV . Subjects history current evidence uncontrolled hypertension define systolic blood pressure &gt; 150 mmHg diastolic blood pressure &gt; 95 mmHg screen despite optimal medical management . Subjects history current evidence malignant biliary obstruction require biliary stent . Subjects solid organ bone marrow Transplantation . Subjects history hypersensitivity study drug excipients , history severe hypersensitivity Antigen . Subjects history human immunodeficiency virus ( HIV ) infection subject active hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) infection require treatment . Subjects active clinically serious infection CTCAE Grade ≥2 nonhealing wound unrelated primary Tumor . Subjects received systemic cancer therapy , radiotherapy , granulocyte colonystimulating factor , ( GCSF ) granulocyte macrophagestimulating factor ( GMCSF ) , erythropoietinstimulating agent , investigational drug treatment outside study within 4 week start study treatment , drug know renal toxicity strong cytochrome P450 3A4 ( CYP3A4 ) inhibitor strong CYP3A4 inducer . Subjects start oral parenteral anticoagulation therapy within 2 week start anetumab ravtansine end treatment visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>Solid tumor</keyword>
	<keyword>Mesothelioma</keyword>
	<keyword>Lung cancer</keyword>
	<keyword>Pemetrexed</keyword>
	<keyword>Cisplatin</keyword>
</DOC>